- Healthcare 150
- Posts
- The $10.7B Pharma Deal Reshaping European Healthcare
The $10.7B Pharma Deal Reshaping European Healthcare
We’re unpacking the forces slowing healthcare M&A acceleration in 2026, CVC’s €10.7B bet on European pharma, the rise of oral GLP-1 therapies as scalable healthcare infrastructure, and how Europe and Asia are emerging as a new global healthcare capital axis.
Good morning, ! This week we’re unpacking the forces slowing healthcare M&A acceleration in 2026, CVC’s €10.7B bet on European pharma, the rise of oral GLP-1 therapies as scalable healthcare infrastructure, and how Europe and Asia are emerging as a new global healthcare capital axis.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
MICROSURVEY
What’s the Biggest Barrier to Healthcare M&A Acceleration in 2026? |
DEAL OF THE WEEK
Rx Deal Pulse: CVC’s €10.7B Bet on European Pharma
CVC Capital Partners and Groupe Bruxelles Lambert have launched a €10.7 billion take-private bid for Italian specialty pharma group Recordati, marking one of the largest European healthcare buyouts in recent years. The consortium, backed by ADIA and CPP Investments, is offering €67 per share to minorities after already securing control of roughly 47% of the company. The transaction underscores renewed sponsor appetite for scaled pharma assets with durable cash flows, orphan drug exposure and resilient margins amid a recovering leveraged finance market.
Recordati has become a highly attractive platform due to its rare disease franchise, strong European footprint and consistent EBITDA generation. The deal also highlights continuing convergence between long-duration infrastructure-style capital and traditional private equity in defensive healthcare sectors. If completed, the acquisition would rank among the most significant healthcare LBOs in Europe since the post-pandemic slowdown in mega-deals.
Advisors include Goldman Sachs, Morgan Stanley and Mediobanca on financing and strategic matters, while legal counsel reportedly includes Kirkland & Ellis and Chiomenti. (More)
PRESENTED BY EXACT INSIGHT
The difference between a rushed diligence process and a high-conviction one often comes down to the quality of the inputs behind it.
Exact Insight helps PE firms and investment bankers scope verified primary research for due diligence, market sizing, operator and customer validation, and portfolio monitoring. Invitation-only panels. AI-powered matching and fraud detection. Human verification. Quant, qual, and hybrid studies delivered quickly.
Share the question your team needs answered, and Exact Insight will respond with a tailored proposal built for your specific use case.
HEADLINE OF THE WEEK
EMA Clears First Oral Wegovy for Europe: Obesity Drugs Move From Injectable Specialty Therapy to Scalable Primary-Care Infrastructure.
The European Medicines Agency’s recommendation to approve Novo Nordisk’s oral Wegovy marks a pivotal shift in the $100B+ obesity market, opening the door for GLP-1 treatment to scale beyond injection capacity limits and specialist clinics into mainstream primary care, retail pharmacy, and broader employer- and payer-sponsored access models. The move intensifies the race between Novo Nordisk and Eli Lilly and Company to dominate oral obesity therapeutics, a category expected to materially expand the addressable patient population by improving convenience, adherence, and manufacturing scalability. Analysts and regulators increasingly view oral GLP-1s not as line extensions, but as a platform transition capable of reshaping chronic disease management, reimbursement frameworks, and downstream demand across cardiometabolic care.
So What? Healthcare leaders should view oral GLP-1 adoption as a structural market inflection point: it will accelerate payer scrutiny, redistribute care delivery toward primary care and digital channels, pressure healthcare budgets globally, and create new winners across pharma manufacturing, PBMs, diagnostics, employer health, and chronic-care infrastructure. (More)
REGIONAL FOCUS
Europe and Asia Are Building a New Healthcare Capital Axis
The planned merger between London-based Global Healthcare Opportunities and Singapore’s CBC Group creates more than a $21B healthcare investor. It signals a deeper shift in where healthcare capital formation is heading. Europe still brings regulatory depth, mature biotech ecosystems, and established medtech infrastructure.
Asia-Pacific increasingly brings growth velocity, manufacturing scale, and government-backed innovation agendas. Reuters reported the combined platform will span 13 offices across North America, Europe, and Asia-Pacific, regions representing roughly 90% of global healthcare R&D spend.
What matters is not size alone. Cross-border healthcare investing is becoming operationally necessary as AI, biologics, diagnostics, and infrastructure increasingly require regional commercialization strategies rather than single-market execution. GHO gains faster exposure to APAC expansion. CBC gains institutional reach into Europe and North America. That mirrors a broader industry trend we flagged previously. Asia is no longer just a growth market. It is becoming a capital and innovation center in its own right. (More)
"The road to success and the road to failure are almost exactly the same."
Colin R. Davis